- Home
- KPTI vs AVTX Comparison
KPTI vs AVTX Comparison
Compare KPTI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- AVTX
- Stock Information
- Founded
- KPTI 2008
- AVTX 2011
- Country
- KPTI United States
- AVTX United States
- Employees
- KPTI N/A
- AVTX N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- KPTI Health Care
- AVTX Health Care
- Exchange
- KPTI Nasdaq
- AVTX Nasdaq
- Market Cap
- KPTI 44.5M
- AVTX 138.8M
- IPO Year
- KPTI 2013
- AVTX 2015
- Fundamental
- Price
- KPTI $5.86
- AVTX $11.64
- Analyst Decision
- KPTI Buy
- AVTX Strong Buy
- Analyst Count
- KPTI 6
- AVTX 9
- Target Price
- KPTI $39.80
- AVTX $30.14
- AVG Volume (30 Days)
- KPTI 97.1K
- AVTX 188.1K
- Earning Date
- KPTI 11-04-2025
- AVTX 11-06-2025
- Dividend Yield
- KPTI N/A
- AVTX N/A
- EPS Growth
- KPTI N/A
- AVTX N/A
- EPS
- KPTI N/A
- AVTX N/A
- Revenue
- KPTI $137,269,000.00
- AVTX $441,000.00
- Revenue This Year
- KPTI $3.40
- AVTX N/A
- Revenue Next Year
- KPTI $9.69
- AVTX N/A
- P/E Ratio
- KPTI N/A
- AVTX N/A
- Revenue Growth
- KPTI N/A
- AVTX N/A
- 52 Week Low
- KPTI $3.51
- AVTX $3.39
- 52 Week High
- KPTI $16.95
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- KPTI 47.41
- AVTX 64.74
- Support Level
- KPTI $6.15
- AVTX $9.54
- Resistance Level
- KPTI $6.85
- AVTX $12.41
- Average True Range (ATR)
- KPTI 0.50
- AVTX 1.06
- MACD
- KPTI -0.17
- AVTX -0.04
- Stochastic Oscillator
- KPTI 10.39
- AVTX 81.12
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).